The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
Drug Design, Development and Therapy · 2023-09 · Volume 17 · 2691-2725
DOI: 10.2147/dddt.s424991 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023-09. Verfasst von Sarfaraz K Niazi. Beteiligte Einrichtung: College of Pharmacy, University of Illinois, Chicago, IL, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Machine Learning. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 314 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, University of Illinois, Chicago, IL, USA.
ORCID-Profile: Sarfaraz K Niazi
Zitieren
APA
Niazi, S. K. (2023). The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives. Drug Design, Development and Therapy, Volume 17, 2691-2725. https://doi.org/10.2147/dddt.s424991
Vancouver
Niazi SK. The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives. Drug Design, Development and Therapy. 2023;Volume 17:2691-2725. doi:10.2147/dddt.s424991
BibTeX
@article{Niazi2023,
author = {Niazi, Sarfaraz K},
title = {The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives},
journal = {Drug Design, Development and Therapy},
year = {2023},
volume = {Volume 17},
pages = {2691--2725},
doi = {10.2147/dddt.s424991}
}
EUVIMED